{"filings":[{"id":101896,"accession_number":"0001213900-26-035499","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"ABVC BioPharma shareholders re-elect 11 directors, ratify auditor, approve equity plan increase at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 11 incumbent directors re-elected with overwhelming support (over 98% for each nominee).","Ratification of Simon & Edward, LLP as independent auditor for FY 2026: 10,597,352 for, 12,291 against.","Equity incentive plan increase approved: 9,964,400 for, 643,419 against; shares reserved now 15% of outstanding.","Quorum established with 10,612,493 shares (41.74% of voting power) present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101895,"accession_number":"0001213900-26-023054","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","4.02","9.01"],"status":"ready","headline":"ABVC BioPharma concludes Q3 2025 financials unreliable; total assets surge 179% to $21.06M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board determined Q3 2025 financials unreliable due to revenue recognition errors ($795,950 reversed) and land valuation error ($798,486 increase).","Company will restate Q3 2025 10-Q; identifies material weakness in internal controls over financial reporting.","FY2025 total assets $21.06M (179% YoY); property/equipment $12.84M (up from $0.51M).","Strategic land acquisitions in Taiwan valued at ~$4.6M (Longtan) and ~$8.0M (Puli) strengthen asset base.","Revenue and EPS not disclosed; licensing model retains economics while reducing cash burn."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101894,"accession_number":"0001213900-26-005165","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K/A","filed_at":"2026-01-16T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"ABVC BioPharma completes $2.28M additional unregistered offering, issues 1.5M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["From May 26, 2025 to Jan 6, 2026, ABVC accepted additional subscriptions totaling $2,275,468 under same terms as prior Reg S offering.","Issued 1,500,250 shares of common stock at prices ranging from $1.00 to $1.95 per share.","Shares represent approximately 5.92% of outstanding common stock as of filing date.","All purchasers are non-U.S. persons (accredited investors); voting rights transferred to Chairman Eugene Jiang via proxy agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118233,"accession_number":"0001213900-25-104900","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ABVC BioPharma Q3 2025 licensing revenue up 230% YoY to $1.28M; total assets rise 181%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Licensing revenue of $1.28M in Q3 2025 vs $0.39M in Q3 2024 (+230% YoY).","Total assets $21.18M (Sep 30, 2025) vs $7.54M (Dec 31, 2024); up 181%.","Property and equipment surged to $12.06M from $0.51M (+2,100%) on land buys in Taiwan.","Two land acquisitions completed in Q3: Puli ($7.67M) and Longtan ($3.3M) for R&D and API cultivation.","Company maintains asset-light licensing model with multiple CNS, ophthalmology, oncology licensing agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":795950.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118232,"accession_number":"0001213900-25-103799","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ABVC BioPharma approves performance incentive plan contingent on $1B market cap by Dec 31, 2027","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Plan grants up to 1% of outstanding shares, capped at $10M total and $1M per recipient.","Effective only if ABVC maintains $1B market cap for 30 consecutive trading days before 2027 deadline.","Shares come from Amended 2016 Equity Incentive Plan; allocation set by Compensation Committee and Board.","No guarantee the condition will be met; plan may never be implemented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134667,"accession_number":"0001213900-25-086952","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K/A","filed_at":"2025-09-12T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"ABVC Biopharma: Former auditor WWC refused to provide letter agreeing with 8-K statements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["WWC, P.C. agreed not to renew engagement on October 10, 2024.","Company requested WWC provide letter to SEC agreeing with 8-K disclosures.","As of September 12, 2025 filing, WWC has refused to provide such letter.","No reason for refusal or any disagreement disclosed in the amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134668,"accession_number":"0001213900-25-076018","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ABVC BioPharma reports Q2 2025 results with 103% asset growth and $350K licensing revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total consolidated assets increased 103% to $16.2 million from $8.0 million in Q2 2024","Shareholders' equity rose to $9.5 million from $8.0 million year-over-year","Diluted loss per share improved to $(0.13) from $(0.42) full-year 2024 loss","Acquired farmland in Taiwan valued at approximately $3.3 million for R&D and GMP expansion","Received $350,000 in licensing revenue from AiBtl BioPharma, OncoX BioPharma, and ForSeeCon Eye Corporation in July 2025"],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134666,"accession_number":"0001213900-25-065728","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K/A","filed_at":"2025-07-18T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"ABVC issues 2.04M shares + 1M warrants for Taiwan land from director Shuling Jiang","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 2,035,136 restricted shares to Jiang for land valued at $3.86M, plus assumption of $500K bank liability.","Warrant to purchase 1M shares at $2.50/share (cashless exercise); potential 5-year term.","Separate consulting agreement grants 1M shares vesting 200K/yr over 5 years for land development services.","Jiang's ownership could reach 23.3% of outstanding shares post-issuance and vesting (from current 8.16%).","Reversion right if ABVC delists or change of control; price adjustment if stock falls below $1.65 before shares tradable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151567,"accession_number":"0001213900-25-051144","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"ABVC BioPharma shareholders approve all four proposals including related-party land deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["11 directors re-elected with ~5.9M votes for each; 18,525 withheld per director.","Simon & Edward, LLP ratified as auditor for FY2025 with 5,903,606 votes for.","Land purchase from director Shuling Jiang approved (5,832,130 for); may exceed 20% of outstanding shares.","Equity incentive plan increased to 15% of outstanding shares with annual auto-increase approved (5,691,168 for).","Quorum of 5,917,309 shares (35.27% voting power) present for annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151563,"accession_number":"0001213900-25-049491","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K/A","filed_at":"2025-05-30T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"ABVC BioPharma accepts additional $670K in Reg S offering, issuing 957,144 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial Reg S offering (Apr 30–May 9) sold 1,030,413 shares for aggregate gross proceeds ~$619,625.","On May 27, accepted additional subscriptions of $670,000 for 957,144 shares on same terms as initial offering.","All shares sold to non-U.S. persons under Regulation S; voting rights transferred to chairman Eugene Jiang.","Combined gross proceeds from both tranches total ~$1.29 million; shares unregistered for one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151562,"accession_number":"0001213900-25-043354","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K/A","filed_at":"2025-05-14T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"ABVC BioPharma raises ~$619k via unregistered share sales to non-U.S. persons","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On April 30, 2025 sold 724,372 shares for ~$436k to 15 non-U.S. persons under Regulation S.","Additional subscriptions from May 9-13, 2025: 306,041 shares for ~$183,625 from 7 non-U.S. persons.","Each investor transferred voting rights to chairman Eugene Jiang via Voting Rights Proxy Agreement.","Shares are unregistered, restricted for one year, and sold without general solicitation.","Total gross proceeds from both tranches approximate $619,625."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151561,"accession_number":"0001213900-25-042982","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K/A","filed_at":"2025-05-14T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"ABVC BioPharma regains Nasdaq minimum bid price compliance; reports 234% revenue growth in FY2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Regained compliance after maintaining $1.00 bid price for 10 consecutive days through May 12, 2025.","FY2024 revenue increased 234% YoY; operating expenses reduced 21%; EPS improved 77%.","Secured three licensing partnerships with potential $7M upfront and up to $660M in milestones.","Received approximately $0.5M in upfront payments in FY2025 year-to-date.","Preliminary discussions underway with pharma and AI firms for co-developing Phase III-ready MDD and ADHD candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151560,"accession_number":"0001213900-25-040194","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K/A","filed_at":"2025-05-06T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"ABVC BioPharma regains Nasdaq compliance after equity shortfall notice","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On April 30, 2025, Nasdaq notified ABVC that stockholders' equity of $723,959 as of April 23 failed Listing Rule 5550(b)(1).","On May 5, 2025, Nasdaq confirmed compliance after ABVC's Q1 2025 10-Q showed equity of $7,956,295, closing the matter.","The company avoided delisting by demonstrating equity above the required minimum through its quarterly filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151559,"accession_number":"0001213900-25-039184","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K/A","filed_at":"2025-05-02T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"ABVC BioPharma says 2023 financials error resolved in filed 10-K, no amendment needed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Original 8-K on Apr 15, 2025 flagged 2023 financials for errors, requiring amendment.","After discussions with auditor Simon & Edward LLP, management determined corrections adequately addressed in the 2024 10-K filed Apr 15, 2025.","Company will not file the previously planned 2023 Amendment; prior non-reliance is effectively rescinded.","Auditor Simon & Edward LLP concurred with management's conclusion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151566,"accession_number":"0001213900-25-038060","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ABVC BioPharma Q1 net loss narrows 68% to $944K; eyes AI agriculture in Taiwan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share improved to $(0.06) from $(0.29) in Q1 2024.","Total operating expenses reduced 76% to $693,005.","Net loss attributable to ABVC was $842,075, down from $2.83M.","Recognized a land asset in Taiwan valued at $7.67M for potential AI-integrated GAP-compliant plant factory.","Company evaluating development of AI-driven agricultural facility for sustainable botanical supply chain."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151565,"accession_number":"0001213900-25-037654","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["3.01","3.02","9.01"],"status":"ready","headline":"ABVC receives Nasdaq delisting notice for low equity; raises $436K in stock sale","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified ABVC on April 24 that stockholders' equity of $723,959 is below the $2.5M minimum for continued listing.","ABVC has 45 days to submit a compliance plan; if accepted, it may have until Oct 21, 2025 to regain compliance.","Sold 724,372 common shares to 15 non-U.S. persons for gross proceeds of ~$436,000 under Regulation S.","Each purchaser agreed to transfer voting rights to Chairman Eugene Jiang via a Voting Rights Proxy Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151558,"accession_number":"0001213900-25-032468","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K/A","filed_at":"2025-04-16T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ABVC FY2024 revenue $509.6K (+234%), net loss narrows 77% to $4.9M, EPS $(0.42)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue surged 234% to $509,589 driven by licensing milestones.","Net loss improved to $4.90M from $7.79M; EPS improved 77% to $(0.42).","Operating expenses reduced 21% to $5.21M, R&D down 83%, SG&A down 58%.","Stock-based compensation increased to $2.77M from $0.19M to preserve cash.","Remaining milestone potential of up to $18.3M under existing licensing deals."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151564,"accession_number":"0001213900-25-032135","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["2.02","4.02","7.01","9.01"],"status":"ready","headline":"ABVC BioPharma reports 2024 revenue up 234%, EPS improves 77%, but restates FY2023 financials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revenue $509,589 (+234% YoY); net loss narrowed to $4.90M; EPS improved 77% to ($0.42).","Operating expenses cut 21% to $5.21M; SG&A down 58%, R&D down 83%.","Remaining milestone payments potential of $18.3M from licensing partners.","Board concludes FY2023 financials should no longer be relied upon due to errors in share-based payments, interest, non-controlling interest.","Material weakness in internal controls over financial reporting identified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170431,"accession_number":"0001213900-25-021713","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Leeds Chow resigns; CEO Uttam Patil named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leeds Chow resigned as CFO of ABVC Biopharma effective March 5, 2025.","CEO Uttam Patil will serve as interim CFO during the search for a permanent replacement.","The company is actively seeking a full-time CFO to fill the vacancy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170429,"accession_number":"0001213900-25-002769","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K/A","filed_at":"2025-01-13T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"ABVC BioPharma granted additional 180-day Nasdaq bid price compliance extension to July 7, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq extended deadline from January 6, 2025 to July 7, 2025 for minimum $1.00 bid price requirement.","Company must close at $1.00 or higher for at least 10 consecutive trading days to regain compliance.","ABVC may consider a reverse stock split to meet the bid price requirement.","No immediate impact on Nasdaq listing; stock continues trading under symbol ABVC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170430,"accession_number":"0001213900-25-001211","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"ABVC BioPharma agrees to reduce warrant exercise price to $0.40 for 1.03M shares, raising $412k","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lind Global Fund exercises 1,029,167 warrants at reduced price of $0.40/share, generating $411,666.80 in proceeds.","The company agrees to a 15-day standstill on further common stock issuances, with exceptions for employee plans and strategic transactions.","Resale of the underlying shares is already registered on Form S-1 (File 333-280411).","Company reimburses $3,000 of Holder's legal fees, withheld from exercise proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187415,"accession_number":"0001213900-24-097894","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ABVC BioPharma Q3 revenue $389K, net loss narrows to $134K; first operational profit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $389,276 in Q3 2024 vs $15,884 in Q3 2023, a 2,350% increase.","Net loss narrowed to $134,272 from $3.37M; EPS improved to -$0.02 from -$0.82.","Cash balance grew to $137,344 vs $60,155 at year-end 2023.","Achieved first operational profit but higher interest from convertible debt kept EPS negative.","Licensing agreements could provide up to $292 million; $496K milestone cash received in 9 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":507623.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187414,"accession_number":"0001213900-24-094178","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"ABVC BioPharma induces Lind Global to exercise 500,000 warrants at $0.42/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lind exercises 500,000 existing warrants at reduced price of $0.42/share, generating approx. $210,000 in cash.","Company grants Lind no new warrants; remaining warrants unchanged at $0.75 and $1.00 strike prices.","Company agrees to 45-day halt on equity issuances and one-year ban on variable rate transactions.","Lind receives customary representations and indemnification; company will file 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187413,"accession_number":"0001213900-24-089013","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"ABVC BioPharma auditor WWC P.C. declines renewal; Simon & Edward LLP appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["WWC agreed not to renew engagement effective Oct 10, 2024; Board approved non-renewal on Oct 17.","Board approved engagement of Simon & Edward, LLP as new independent registered public accounting firm on Oct 17.","WWC's reports for FY2022-2023 and interim Jun 2024 had no adverse opinion except a going concern paragraph.","No disagreements or reportable events between Company and WWC during the relevant periods.","Prior consultations with S&E regarding accounting principles or disagreements did not occur."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203929,"accession_number":"0001213900-24-077361","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ABVC Biopharma regains compliance with Nasdaq Shareholder Approval Rules","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notification on Sept 6, 2024 confirming compliance with Listing Rules 5635(a)(1) and 5635(a)(2).","Compliance based on Board Resolution dated May 16, 2024.","Regained compliance for continued listing on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203928,"accession_number":"0001213900-24-071145","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ABVC BioPharma updates corporate presentation; no material new details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company filed Form 8-K furnishing an updated corporate presentation on August 20, 2024.","Filing text and exhibit provide no specific financial data, milestones, or strategic changes.","No guidance, partnerships, product developments, or other substantive updates revealed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203927,"accession_number":"0001213900-24-069338","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ABVC BioPharma Q2 2024 EPS improves 86.8% to -$0.09; licensing deals worth up to $292M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["EPS improved 86.8% YoY to -$0.09 in Q2 2024 from -$0.68; revenue surged to $117,142 from $6,109.","Executed global licensing agreements for Vitargus (up to $187M) and oncology products (up to $105M) totaling potential $292M.","Received $116,000 cash milestone in June 2024 from Vitargus licensing.","Shareholders' equity stood at $7.8M as of June 30, 2024.","Obtained US, Taiwanese, and Australian patents for Polygala extract for MDD and ADHD; FDA approved four INDs for oncology."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":118347.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203926,"accession_number":"0001213900-24-063627","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"ABVC BioPharma CFO suspends work amid salary dispute; company corrects license fee numbers downward","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Leeds Chow suspends work due to disagreements over salary owed; CEO Uttam Patil becomes interim CFO.","Potential aggregate license fee corrected from $24M to $19M in prior press release.","Total possible cash payment from licensees corrected from $23.7M to $18.7M.","Disagreement limited to salary; not related to public filings disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203925,"accession_number":"0001213900-24-061028","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"ABVC BioPharma receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on July 10, 2024 for non-compliance with minimum $1.00 bid price rule over 30 consecutive days.","Compliance deadline is January 6, 2025; can regain if bid price closes at $1.00+ for 10 business days.","If not cured, may qualify for additional 180-day period if other initial listing standards are met.","Company may consider a reverse stock split to cure the deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220563,"accession_number":"0001213900-24-055809","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K/A","filed_at":"2024-06-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ABVC BioPharma amends licensing deal to allow $3.5M milestone paid incrementally","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On June 23, 2024, ABVC and BioLite amended licensing agreements with AiBtl BioPharma for CNS drugs MDD and ADHD.","The $3.5M second milestone payment can now be paid in increments (e.g., $50,000) at any time instead of lump sum.","Amendments apply to both the ABVC and BioLite license agreements; no other terms were changed.","Change suggests potential liquidity strain at licensee AiBtl BioPharma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220562,"accession_number":"0001213900-24-055288","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K/A","filed_at":"2024-06-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ABVC BioPharm amends ophthalmology license deal to allow incremental milestone payments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ABVC and BIOFIRST amended licensing agreement with ForSeeCon Eye Corp (FEYE) covering ophthalmology pipeline including Vitargus.","Second milestone payment of $3.5M can now be paid incrementally (e.g., $100k) at any time, rather than a single lump sum.","Amendment dated June 18, 2024; all other terms of the original March 25, 2024, license remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220569,"accession_number":"0001213900-24-046419","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ABVC licenses MDS drug BLEX 404 to OncoX; eligible for $13.75M in fees plus royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ABVC and subsidiary BioLite grant OncoX exclusive rights to develop/commercialize BLEX 404 for MDS in 50% of global markets for 20 years.","Upfront license fee of $12.5M (cash or OncoX shares) due in 30 days; additional $1.25M milestone after OncoX's next fundraising (no guarantee).","ABVC entitled to 5% royalties on net sales, capped at $12.5M, after product launch (uncertain).","BLEX 404 is a β-glucan extract from Maitake mushroom; FDA has approved four INDs for ABVC's oncology pipeline including ABV-1702 for MDS.","No guarantee any fees or royalties will be received; partnership is early-stage and contingent on OncoX's fundraising and commercial success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220568,"accession_number":"0001213900-24-046313","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"ABVC Biopharma induces Lind Global to exercise 1M warrants at $0.75, issues new 1M warrant at $1.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lind Global exercises 1,000,000 existing warrants at reduced price of $0.75/share, generating $750,000 cash proceeds.","Company issues new 5-year warrant to purchase 1,000,000 shares at $1.00/share.","Company must register new warrant shares within 30 days, effective within 60 days, or pay $15,000/week penalty.","Placement agent Allele Capital receives 2% cash fee on warrant exercise proceeds.","Warrants stem from previous securities purchase agreements dated Feb 2023, Nov 2023, and Jan 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220561,"accession_number":"0001213900-24-044798","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K/A","filed_at":"2024-05-17T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"ABVC BioPharma terminates land transfer agreement with director Shuling Jiang","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board terminated agreement to acquire land in Taoyuan City, Taiwan from director Shuling Jiang on May 16, 2024.","Jiang is a director, married to Chief Strategic Officer, and owns ~10% of ABVC common stock.","Company may reconsider the transaction at a later date; no penalty or financial impact disclosed.","Original agreement was reported on Feb 8, 2024; termination is effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220567,"accession_number":"0001213900-24-043229","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ABVC BioPharma licenses BLEX 404 for TNBC to OncoX in deal worth up to $13.75M plus royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Definitive license agreement with OncoX BioPharma for exclusive rights to develop and commercialize BLEX 404 for TNBC in 50% of worldwide markets for 20 years.","Total license fee of $6.25M (or 1.25M OncoX shares at $5/share) due 30 days after signing; additional milestone of $625k cash after OncoX's next fundraising (no guarantee).","ABVC and its subsidiary BioLite each signed identical agreements; aggregate potential payments including royalties up to $13.75M (press release states $12.5M license fee and $1.25M milestone).","Royalties of 5% of net sales on licensed product, up to $12.5M, starting from first commercial sale (uncertain).","US FDA has approved four INDs for ABVC's BLEX 404 combination therapy, including for TNBC (IND 129575)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220566,"accession_number":"0001213900-24-041053","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ABVC licenses BLEX 404 to OncoX for pancreatic cancer; up to $13.75M in fees plus royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ABVC grants OncoX exclusive rights to develop/commercialize BLEX 404 for pancreatic cancer in 50% of worldwide markets for 20 years.","OncoX to pay $6.25M (or 1.25M shares at $5) within 30 days; additional $0.625M milestone after next fundraising (no guarantee).","ABVC entitled to 5% royalties on net sales, up to $12.5M; also may receive cash payments of at least $100K toward licensing fees.","Press release states aggregate expected income of $13.75M and royalties up to $12.5M, but commercialization remains uncertain.","Four FDA INDs approved for ABVC's oncology pipeline; ABV-1703 (BLEX 404) for pancreatic cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220565,"accession_number":"0001213900-24-034583","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"ABVC BioPharma shareholders re-elect 11 directors, ratify auditor, approve equity plan increase at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 11 director nominees were re-elected; quorum of 5,736,015 shares (54.31%) represented.","Ratified WWC P.C. CPA as independent auditor for FY2024 with 5,449,292 votes for.","Approved issuance of shares exceeding 20% of outstanding stock to Lind Global Fund II under convertible notes/warrants.","Increased Amended 2016 Equity Incentive Plan to 1,283,002 shares (12.15% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220564,"accession_number":"0001213900-24-033598","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2024-04-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ABVC signs exclusive license deal with OncoX for NSCLC drug; up to $13.75M in fees + up to $12.5M royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["License for ABVC's single-herb botanical extract from Maitake Mushroom (BLEX 404) for NSCLC in North America for 20 years.","Aggregate license fee of $12.5M (cash or OncoX shares) due within 30 days of signing; additional $1.25M milestone after OncoX's next fundraising (no guarantee).","ABVC and affiliate Rgene also entitled to 5% royalties on net sales, capped at $12.5M, post-commercial launch.","FDA has approved IND for ABV-1519 (BLEX 404) as combination therapy with chemotherapy for NSCLC.","OncoX is a private BVI company specializing in oncology dietary supplements; deal leverages ABVC's clinical-stage pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240200,"accession_number":"0001213900-24-025793","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ABVC enters global licensing deal for Vitargus; potential total fees of $33.5M plus royalties up to $60M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["20-year exclusive global license with ForSeeCon Eye Corp for ophthalmology pipeline including Vitargus.","ABVC and co-development partner BioFirst each to receive $30M upfront (cash or 5M shares of FEYE at $6/share) within 30 days.","Additional $3.5M cash milestone per party after next fundraise; 5% royalty on net sales capped at $60M per entity.","Vitargus valued at $187M by third-party valuer; ABVC retains R&D role for ophthalmic products.","License covers clinical trial, registration, manufacturing, supply, and distribution rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240199,"accession_number":"0001213900-24-022451","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"ABVC BioPharma amends bylaws to reduce shareholder quorum to 33-1/3%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amendment to Section 2.8 of Bylaws on March 14, 2024.","Quorum requirement lowered from a majority to 33-1/3% of votes entitled to be cast.","Amendment effective immediately as of March 14, 2024.","Exhibit 3.2 (Amendment to Bylaws) filed with the SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240198,"accession_number":"0001213900-24-022396","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ABVC BioPharma FY2023 revenue falls 84% to $152K; net loss narrows to $10.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $152,430 in FY2023, down from $969,783 in FY2022; net loss improved 31% to $10.9M.","Operating expenses cut to $8.07M from $15.8M; cash and cash equivalents only $60K as of Dec 31, 2023.","Entered global licensing agreement with AIBL for CNS drugs; received 23M AIBL shares valued at $10 per share.","Regained Nasdaq compliance for $1.00 bid price and $2.5M stockholders' equity requirements in Aug/Sep 2023.","Stockholders' equity of $8.39M at year-end; raised $1.75M via registered direct offering in July 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240194,"accession_number":"0001213900-24-018526","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K/A","filed_at":"2024-02-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ABVC BioPharma amends convertible note with $1.00 floor price; cash payment on floor conversions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to $1M secured convertible note sets floor conversion price at $1.00 per share.","Cash payment required if conversion price equals floor price, based on formula linked to VWAP.","Initial shareholder meeting deadline extended one month to April 17, 2024.","Amendment adopted to comply with Nasdaq listing requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240193,"accession_number":"0001213900-24-018524","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K/A","filed_at":"2024-02-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ABVC BioPharma amends convertible note with Lind: imposes $1 floor conversion price","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment to $1.2M secured convertible note sets conversion floor at $1.00, per Nasdaq requirements.","If conversion price hits floor, company must make cash payment to Lind based on formula (A-B)*C.","Lind also received a 5-year warrant to buy 1M shares at $2/share (unchanged from original).","Note originally issued Nov 17, 2023 for $1M purchase price, $1.2M principal.","Amendment waives any prior events of default under transaction documents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240197,"accession_number":"0001213900-24-011360","cik":1173313,"company_name":"ABVC BIOPHARMA, INC.","ticker":"ABVC","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"ABVC BioPharma acquires $2.96M Taiwan land via stock & warrants in related-party deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Land valued at ~$2.96M; consideration is 703,495 restricted shares at $3.50/share plus 5-yr warrants for 1M shares at $2.00.","Seller Shuling Jiang is a director, holds ~10% of ABVC stock, and is married to the Chief Strategic Officer.","Land to be used for GAP plant factories for botanical drug raw materials; closing targeted by March 10, 2024.","Stock issuance exempt under Section 4(a)(2) and Regulation S; no registration for the unregistered shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":35620603.19424461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}